The short version of GHRH fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-19. Anything still debated is marked as such rather than presented as settled.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
== Medical uses == Omaveloxolone is indicated for the treatment of Friedreich's ataxia. Friedreich's ataxia causes progressive damage to the spinal cord, peripheral nerves, and the brain, resulting in uncoordinated muscle movement, poor balance, difficulty walking, changes in speech and swallowing, and a shortened lifespan. The condition can also cause heart disease. This disease tends to develop in children and teenagers and gradually worsens over time. Although rare, Friedreich's ataxia is the most common form of hereditary ataxia in the United States, affecting about one in every 50,000 people.
Known in antiquity to such medical doctors as Hippocrates and Galen, noma was once reported around the world, including in Europe and the United States. The disease was well-known in the Netherlands in the 1500s and 1600s. The first clinical description of noma was in 1595 by a Dutch man, Carolus Battus. Dutch surgeon Cornelis van de Voorde first used the term "noma" to describe the disease in 1680. A European scientist, Gabriel Lund, attributed noma to poverty, cramped living conditions, and malnutrition in 1765. English medical doctor John Addington Symmonds linked the disease to previous infection with measles. The first surgical treatment for noma sequelae was performed in 1781. Surgical treatments for sequelae developed throughout the 1800s. In the late 1800s, scientists suspected that noma was caused by bacteria. With improvements in hygiene and nutrition, noma has disappeared from industrialized countries since the 20th century, except during World War II when it was endemic to the Auschwitz and Belsen concentration camps. The disease and treatments were studied by Berthold Epstein, a Czech medical doctor and forced-labor prisoner who had recommended the study under Josef Mengele's direction. Since 1970, there has been little research done on noma, with few exceptions. One such exception is Cyril Enwonwu, a Nigerian scientist focusing on noma.
The United States Department of Energy, National Science Foundation, NASA, industry, and nine universities pooled resources to access supercomputers from IBM, combined with cloud computing resources from Hewlett Packard Enterprise, Amazon, Microsoft, and Google, for drug discovery. The COVID-19 High Performance Computing Consortium attempted to forecast disease spread, model vaccines, and screen thousands of chemical compounds. The Consortium had used 437 petaFLOPS of computing power by May 2020. The C3.ai Digital Transformation Institute, an additional consortium of Microsoft, six universities (including MIT), and the National Center for Supercomputer Applications in Illinois, working under the auspices of artificial intelligence software company C3.ai pooled supercomputer resources toward drug discovery, medical protocol development and public health strategy improvement, as well as awarding grants for similar purposes.
Sources: en.wikipedia.org
== Genetics == Chinese landraces were found to have a slightly higher genetic diversity than inbred lines by Li et al., 2010. Specific locus amplified fragment sequencing (SLAF-seq) has been used by Han et al., 2015 to study the genetic history of the domestication process, perform genome-wide association studies (GWAS) of agronomically relevant traits, and produce high-density linkage maps. An SNP array was developed by Song et al., 2013 and has been used for research and breeding; the same team applied their array in Song et al., 2015 against the USDA Soybean Germplasm Collection and obtained mapping data that are expected to yield association mapping data for such traits. Rpp1-R1 is a resistance gene against soybean rust. Rpp1-R1 is an R gene (NB-LRR) providing resistance against the rust pathogen Phakopsora pachyrhizi. Its synthesis product includes a ULP1 protease. Qijian et al., 2017 provides the SoySNP50K gene array.
Bohr model Also Rutherford–Bohr model. A model of the general structure of the atom proposed by Niels Bohr and Ernest Rutherford in 1913, featuring a small, dense nucleus of positively charged particles surrounded by orbiting electrons, which are attracted to the nucleus by electrostatic forces. This interpretation replaced several earlier hypotheses and quickly became the prevailing standard model for depicting atomic structure.
For voluntary and charitable services to the community in Limavady, County Londonderry. David Gregory Snook. Reading Volunteer, Hampton Primary School, Herne Bay, Kent. For services to Education. Versha Sood-Mahindra. Lately Dementia Lead, BUPA. For services to Community Cohesion and to People with Dementia in Cardiff. Zoe Donna Sookun. Project Manager, Network Rail. For services to the Railway and to Rail Aid for Ukraine. Denise Speight. Chargehand Cleaner, Newcastle City Council. For services to Local Government. Charlotte Jessica Stacey. On Call Firefighter, Oxfordshire Fire and Rescue Service. For services to the community in Oxfordshire. Margaret Pearl Sterling. Teaching Associate, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast. For services to Higher Education in Northern Ireland. Eileen Linda Stewart. Manager, Armagh Business Centre. For services to Entrepreneurship, to Economic Regeneration and to the community in Armagh, Northern Ireland. Gloria Ann Stewart. For services to the community in Sheffield, South Yorkshire. Sheena Stewart. Lately Warden, Chalmers Court Sheltered Housing Complex, Inverarary. For services to the community in Mid-Argyll. Allan Stokoe. For services to the community in Eldon, North Yorkshire. Dr Jill Mary Stoner. Chair, Cromarty Care Project. For services to the community in Cromarty, Ross and Cromarty. Jan Tallis. Founding Chair, Community Schools Trust. For services to Children and Families in the London Borough of Newham. Robert Sherwin Taylor. For services to the community in Shipbourne, Kent.
Scarring during healing can create both physical and psychological problems, and is a significant clinical burden. Collagen, for instance, is abnormally organised in scar tissue; collagen in scars is arranged in parallel bundles of collagen fibers, whilst healthy scar free tissue has a "basket weave" structure (Figure 1). The difference in collagen arrangement along with a lack of difference in the dermal tissue when healing has taken place with or without scarring is indicative of regenerative failure of normal skin. Severe scarring resulting from these collagen deposits is known as hypertrophic scarring and is of great concern worldwide with an incidence ranging from 32–72%.
Sources: en.wikipedia.org
Pterophyllum scalare, most commonly referred to as angelfish or freshwater angelfish, is the most common species of Pterophyllum kept in captivity. It is native to the Amazon Basin in Peru, Colombia, and Brazil. Particularly to the Ucayali river in Peru, the Oyapock River in French Guiana, the Essequibo River in Guyana, the Solimões, the Amapá, and the Amazon rivers in Brazil. It is found in swamps or flooded grounds where vegetation is dense and the water is either clear or silty. Its native waters range from a neutral pH of 7.0 down to near 6.0, with a general water hardness (gH) range of 3 to 10 °dH, and water temperature ranging from 26 to 30 °C (75 to 86 °F). This is the species of angelfish most frequently found in the aquarium trade. A similar (cross-breeding possible) P. scalare exists in the Rio Orinoco. They are of the same size and shape, the only difference being the stripes; the Orinoco P. scalare has thinner, but dual, stripes. The diet of Pterophyllum scalare consists of a wide spectrum of prey; they feed on tiny fish fry and younger, juvenile fishes, young and mature shrimps, crabs, prawns, various worms, mosquito larvae, and water bugs. Additionally, they will opportunistically catch any smaller-sized floating insects that have fallen onto the surface of the water.
The purest metal is obtained from nickel oxide by the Mond process, which gives a purity of over 99.99%. The process was patented by Ludwig Mond and has been in industrial use since before the beginning of the 20th century. In this process, nickel is treated with carbon monoxide in the presence of a sulfur catalyst at around 40–80 °C to form nickel carbonyl. In a similar reaction with iron, iron pentacarbonyl can form, though this reaction is slow. If necessary, the nickel may be separated by distillation. Dicobalt octacarbonyl is also formed in nickel distillation as a by-product, but it decomposes to tetracobalt dodecacarbonyl at the reaction temperature to give a non-volatile solid. Nickel is obtained from nickel carbonyl by one of two processes. It may be passed through a large chamber at high temperatures in which tens of thousands of nickel spheres (pellets) are constantly stirred. The carbonyl decomposes and deposits pure nickel onto the spheres. In the alternate process, nickel carbonyl is decomposed in a smaller chamber at 230 °C to create a fine nickel powder. The byproduct carbon monoxide is recirculated and reused. The highly pure nickel product is known as "carbonyl nickel".
For instance, more public officials are brought within the scope of the directive, and EU member states are required to establish new registries of "beneficial owners" (i.e., those who ultimately own or control each company) which will impact banks. AMLD IV became effective 25 June 2015. On 24 January 2019, the European Commission sent official warnings to ten member states as part of a crackdown on lax application of money laundering regulations. The Commission sent Germany a letter of formal notice, the first step of the EU legal procedure against states. Belgium, Finland, France, Lithuania, and Portugal were sent reasoned opinions, the second step of the procedure which could lead to fines. A second round of reasoned opinions was sent to Bulgaria, Cyprus, Poland, and Slovakia. The ten countries have two months to respond or face court action. The commission had set a 26 June 2017 deadline for EU countries to apply new rules against money laundering and terrorist financing. On 13 February 2019, the Commission added Saudi Arabia, Panama, Nigeria and other jurisdictions to a blacklist of nations that pose a threat because of lax controls on terrorism financing and money laundering. This is a more expansive list than that of FATF.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.